Fundz
New|Fundz now works inside Claude2 min

Discover more near‑term opportunities with better event intelligence.

Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Viking Therapeutics closes upsized offerings of common stock and convertible senior notes. The fundraising includes the full exercise of underwriters' options to purchase additional shares.

PUBLIC · VKTXSep 28, 2026

Round Type

Convertible Note

San DiegoBiotechnology

Description

Viking Therapeutics has successfully closed concurrent offerings of common stock and convertible senior notes. The company reports that the offerings were upsized and included the full exercise of underwriters' options to purchase additional shares. This fundraising effort supports the company's ongoing initiatives and growth strategies. Details surrounding the amounts raised in these offerings have not been disclosed in the headline.

Company Information

Company

Viking Therapeutics

Location

9920 Pacific Heights Blvd,, Suite 350

San Diego, California, United States

About

Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel 1st-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with two programs currently in clinical trials. Viking's clinical programs include VK2735, a novel dual agonist of the GLP-1 and GIP receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial.

Fundz sees it the moment Viking Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMarianne M., Chief Operating OfficerSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Viking Therapeutics's next move

See what Strategic adds

Viking Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.